Synthesis and transport of outer membrane components across the Gram-negative cell envelope
外膜成分的合成和跨革兰氏阴性细胞包膜的运输
基本信息
- 批准号:10680968
- 负责人:
- 金额:$ 57.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-01-27 至 2027-12-31
- 项目状态:未结题
- 来源:
- 关键词:Antibiotic ResistanceAntibioticsAntimicrobial ResistanceAttentionBacteriaBacterial InfectionsBiochemicalBiogenesisBiological ModelsBiologyCellsCessation of lifeClinicalComplexCytoplasmDataDedicationsDevelopmentEncapsulatedEnergy-Generating ResourcesEscherichia coliFamilyFutureGeneticGlycerophospholipidsGram-Negative BacteriaHealthcareHomeostasisHydrophobicityInfectionLipidsLipopolysaccharidesLipoproteinsMaintenanceMembraneMembrane LipidsMembrane ProteinsMethodologyMolecularMolecular ChaperonesMonitorMovementMulti-Drug ResistanceOrganismPathway interactionsPeptidoglycanProteinsReportingResistanceRoleSideSurfaceSystemSystems Analysisantimicrobialaqueousbeta barrelcell envelopedesigneconomic costfightingglobal healthlipid transportlipophilicitymembermembrane assemblymembrane biogenesisnew therapeutic targetnovelnovel therapeuticspathogenperiplasmpreventprotein complex
项目摘要
Abstract
The increasing rise in antibiotic resistance and the diminished discovery of new antimicrobials threatens global
healthcare. Of particular concern are Gram-negative pathogens, organisms with an additional outer membrane
(OM) that provides intrinsic resistance to multiple classes of antibiotics. Unlike the inner membrane (IM) that is
composed solely of glycerophospholipids (GPLs), the OM is asymmetrical with GPLs found in the inner leaflet
and lipopolysaccharide (LPS) localized to the outer leaflet. This unique membrane asymmetry affords
protection from large polar molecules, as well as lipophilic compounds, creating an impervious barrier. Since
the OM is essential, pathways required for its assembly are key targets for antimicrobial design. Currently,
there are no antibiotics that directly target OM biogenesis in clinical use. Thus, it remains critical to investigate
cell envelope biogenesis for future and current antimicrobial design.
Over the last few decades, we have expanded our understanding of OM assembly revealing new targets for
antimicrobial design. However, one major gap remained. How are GPLs transported from the IM to the OM
across the aqueous periplasm? Recently, we discovered that key members of the AsmA-like family (YhdP,
TamB, and YdbH) are critical for OM integrity and involved in GPL transport. We found that YhdP, TamB, and
YdbH are redundant in their role in OM lipid homeostasis; however, they are not equivalent. Notably, all three
proteins share homology and structural features with eukaryotic GPL transporters and are capable of spanning
the periplasm. The overall objective of this application is to investigate the molecular mechanisms required
for the assembly and maintenance of the Gram-negative OM. More specifically, we will characterize pathways
required to transport GPLs across the cell envelope using E. coli as the model system. In the current
application we will (i) characterize the major GPL transporters (YhdP, TamB, and YdbH), (ii) identify accessory
proteins required for GPL transbilayer movement, and (iii) determine how loss of these systems impact OM
lipid homeostasis and antibiotic resistance.
抽象的
抗生素耐药性的日益增加和新抗菌药物发现的减少威胁着全球
卫生保健。特别值得关注的是革兰氏阴性病原体,即具有额外外膜的生物体
(OM) 对多种抗生素具有内在耐药性。与内膜 (IM) 不同的是
OM 仅由甘油磷脂 (GPL) 组成,与内叶中发现的 GPL 不对称
和脂多糖(LPS)位于外叶。这种独特的膜不对称性使得
防止大极性分子以及亲脂性化合物的侵害,形成不透水的屏障。自从
OM 至关重要,其组装所需的途径是抗菌设计的关键目标。现在,
临床上尚无直接针对 OM 生物发生的抗生素。因此,调查仍然至关重要
用于未来和当前抗菌设计的细胞包膜生物发生。
在过去的几十年里,我们扩展了对 OM 组装的理解,揭示了新的目标
抗菌设计。然而,仍然存在一个重大差距。 GPL 如何从 IM 传输到 OM
穿过水性周质?最近,我们发现 AsmA 样家族的关键成员(YhdP、
TamB 和 YdbH)对于 OM 完整性至关重要并参与 GPL 传输。我们发现 YhdP、TamB 和
YdbH 在 OM 脂质稳态中的作用是多余的;然而,它们并不等同。值得注意的是,这三个
蛋白质与真核 GPL 转运蛋白具有同源性和结构特征,并且能够跨越
周质。该应用的总体目标是研究所需的分子机制
用于革兰氏阴性 OM 的组装和维护。更具体地说,我们将描述路径
使用大肠杆菌作为模型系统在细胞膜上运输 GPL 是必需的。在当前
应用程序中,我们将 (i) 描述主要 GPL 传输程序(YhdP、TamB 和 YdbH)的特征,(ii) 识别附件
GPL 跨双层运动所需的蛋白质,以及 (iii) 确定这些系统的丢失如何影响 OM
脂质稳态和抗生素耐药性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael Stephen Trent其他文献
Michael Stephen Trent的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael Stephen Trent', 18)}}的其他基金
The role of cardiolipin in the biogenesis of the Gram-negative bacterial cell envelope
心磷脂在革兰氏阴性细菌细胞包膜生物发生中的作用
- 批准号:
10731444 - 财政年份:2023
- 资助金额:
$ 57.98万 - 项目类别:
The Cell Envelope of the Multi-Drug Resistant Pathogen Acinetobacter baumannii
多重耐药病原体鲍曼不动杆菌的细胞包膜
- 批准号:
10113527 - 财政年份:2020
- 资助金额:
$ 57.98万 - 项目类别:
The Cell Envelope of the Multi-Drug Resistant Pathogen Acinetobacter baumannii
多重耐药病原体鲍曼不动杆菌的细胞包膜
- 批准号:
10542396 - 财政年份:2020
- 资助金额:
$ 57.98万 - 项目类别:
The Cell Envelope of the Multi-Drug Resistant Pathogen Acinetobacter baumannii
多重耐药病原体鲍曼不动杆菌的细胞包膜
- 批准号:
10328269 - 财政年份:2020
- 资助金额:
$ 57.98万 - 项目类别:
Molecular mechanisms required for the maintenance of the gram-negative outer membrane
维持革兰氏阴性外膜所需的分子机制
- 批准号:
10159193 - 财政年份:2018
- 资助金额:
$ 57.98万 - 项目类别:
Molecular mechanisms required for the maintenance of the gram-negative outer membrane
维持革兰氏阴性外膜所需的分子机制
- 批准号:
9917747 - 财政年份:2018
- 资助金额:
$ 57.98万 - 项目类别:
Molecular mechanisms required for the maintenance of the gram-negative outer membrane
维持革兰氏阴性外膜所需的分子机制
- 批准号:
10403653 - 财政年份:2018
- 资助金额:
$ 57.98万 - 项目类别:
Development of a novel vaccine platform: Surface Antigen/Adjuvant Vaccine Engineering (SAAVE)
新型疫苗平台的开发:表面抗原/佐剂疫苗工程(SAAVE)
- 批准号:
9899172 - 财政年份:2017
- 资助金额:
$ 57.98万 - 项目类别:
Rethinking the barrier: How a Gram-negative bacterium alters its surface to become multidrug resistant
重新思考屏障:革兰氏阴性细菌如何改变其表面以产生多重耐药性
- 批准号:
9102680 - 财政年份:2015
- 资助金额:
$ 57.98万 - 项目类别:
相似国自然基金
放线菌吲哚-噁唑类抗生素的生物合成机制及其组合生物合成研究
- 批准号:32360009
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
基于真菌的跨界群体感应干扰对水环境抗生素抗性基因传播的影响及调控研究
- 批准号:42307159
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
附着培养微藻对市政污水中抗生素与常量污染物长效协同净化的调控机制
- 批准号:52370043
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
g-C3N4基原子级超薄S-型异质结构建及抗生素降解机制研究
- 批准号:22308203
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
用于抗生素去除的造纸浆渣基功能化有机高分子絮凝剂的结构调控及构效关系研究
- 批准号:52370015
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
An Integrated Catheter Dressing for Early Detection of Catheter-related Bloodstream Infections
用于早期检测导管相关血流感染的集成导管敷料
- 批准号:
10647072 - 财政年份:2023
- 资助金额:
$ 57.98万 - 项目类别:
Hybrid repellant-antimicrobial gemini coatings for prevention of catheter-associated bloodstream infections
用于预防导管相关血流感染的混合排斥剂-抗菌 Gemini 涂层
- 批准号:
10697071 - 财政年份:2023
- 资助金额:
$ 57.98万 - 项目类别:
Developing a novel class of peptide antibiotics targeting carbapenem-resistant Gram-negative organisms
开发一类针对碳青霉烯类耐药革兰氏阴性生物的新型肽抗生素
- 批准号:
10674131 - 财政年份:2023
- 资助金额:
$ 57.98万 - 项目类别:
Investigating phage therapy for the treatment of urinary tract infections
研究噬菌体疗法治疗尿路感染
- 批准号:
10677257 - 财政年份:2023
- 资助金额:
$ 57.98万 - 项目类别:
Investigating phage therapy for the treatment of urinary tract infections
研究噬菌体疗法治疗尿路感染
- 批准号:
10677257 - 财政年份:2023
- 资助金额:
$ 57.98万 - 项目类别: